cytopatholog
highli
use
noninvas
method
diagnosi
malign
vs
benign
condit
identifi
cation
infecti
agent
howev
number
problem
confront
cytopathologist
daili
basi
limit
convent
cytolog
featur
adjunct
techniqu
util
give
addit
inform
allow
one
reach
defi
nitiv
diagnosi
techniqu
must
use
parallel
convent
cytolog
featur
includ
immunodiagnost
cellular
origin
electron
microscopi
presenc
subcellular
structur
special
histochem
stain
demonstr
chemic
constitu
fl
ow
cytometri
imag
analysi
quantit
evalu
cellular
marker
molecular
diagnost
clonal
chromosom
abnorm
chapter
discuss
adjunct
diagnost
techniqu
focu
applic
cytopatholog
histopatholog
detect
antigen
immunolog
chemic
reaction
tissu
section
immunohistochemistryihc
cytolog
prepar
immunocytochemistryicc
becom
one
commonli
use
ancillari
morpholog
techniqu
diagnost
patholog
barr
wu
advantag
ihc
icc
requir
use
expens
equip
prospect
retrospect
studi
done
varieti
sampl
antigen
detect
correl
morpholog
chang
ihc
cellular
locat
icc
stain
slide
store
mani
month
routin
process
sampl
usual
accept
techniqu
ihc
icc
practic
character
poorli
differenti
neoplasm
differenti
primari
metastat
tumor
determin
site
origin
metastat
lesion
prognost
assess
delelli
hoda
gener
consensu
ihcicc
method
properli
appli
interpret
increas
diagnost
accuraci
patholog
technic
aspect
ihc
icc
interpret
result
pitfal
review
algorithm
approach
diagnosi
tumor
diagnosi
metastat
diseas
use
antibodi
prognost
marker
present
review
includ
detail
ihc
icc
procedur
purpos
reader
refer
publish
materi
polak
van
noorden
ramosvara
saeteel
immunohistochemistri
ihc
demonstr
antigen
tissu
section
incub
section
specifi
c
antibodi
demonstr
immunolog
reaction
histochem
enzymesubstr
reaction
produc
color
visibl
reaction
ramosvara
polyclon
monoclon
antibodi
use
gener
polyclon
antibodi
usual
rais
rabbit
higher
affi
niti
lower
specifi
citi
monoclon
antibodi
crossreact
defi
ned
recognit
unrel
antigen
common
polyclon
antibodi
key
use
polyclon
antibodi
diagnost
ihcicc
degre
purifi
cation
exampl
commerci
avail
antibodi
includ
whole
serum
antibodi
antibodi
purifi
ed
precipit
immunoglobulin
immunoglobulin
purifi
ed
affi
niti
chromatographi
monoclon
antibodi
produc
mice
use
hybridoma
technolog
recogn
singl
epitop
amino
acid
chain
protein
therefor
highli
specifi
c
constant
characterist
among
differ
batch
antibodi
rabbit
monoclon
antibodi
increasingli
use
human
diagnost
ihc
despit
report
advantag
mous
monoclon
antibodi
eg
higher
affi
niti
need
antigen
retriev
use
mous
tissu
neither
react
anim
tissu
perform
better
mous
monoclon
antibodi
reid
et
al
vilchesmour
ramosvara
select
particular
antibodi
determin
publish
inform
experi
laboratori
guarante
c
h
p
e
r
advanc
diagnost
techniqu
ramosvara
ann
c
averi
paul
r
averi
antibodi
recogn
antigen
one
speci
anoth
speci
test
determin
case
needless
say
larg
number
speci
sampl
obtain
one
biggest
challeng
veterinari
pathologist
must
face
immunodiagnost
univers
fi
xativ
histopatholog
diagnost
ihc
buffer
formalin
attempt
replac
formalin
fi
xativ
diagnost
ihc
fail
although
specifi
c
situat
use
nonformaldehyd
fi
xativ
particularli
glyoxalbas
report
yaziji
barri
fixat
necessari
preserv
cellular
compon
prevent
autolysi
displac
cell
constitu
stabil
cellular
materi
antigen
facilit
convent
stain
immunostain
ramosvara
use
formalin
without
problem
first
qualiti
formalin
solut
vari
wide
regard
concentr
formaldehyd
ph
presenc
preserv
second
formalin
fi
xation
produc
methylen
bridg
amino
group
function
group
alter
tertiari
quaternari
structur
protein
form
crosslink
solubl
tissu
protein
chemic
reaction
may
modifi
target
epitop
amino
acid
especi
sensit
formalin
fi
xation
includ
lysin
glycin
tyrosin
arginin
histidin
serin
despit
fact
formalin
fi
xation
may
impair
immunohistochem
detect
good
fi
xation
paramount
detect
antigen
ihc
underfi
xation
bad
wors
overfi
xation
fairli
common
problem
due
reduc
turnaround
time
diagnost
laboratori
advent
heatinduc
epitop
retriev
hier
overfi
xation
variabl
fi
xation
time
among
sampl
less
critic
detect
antigen
target
human
diagnost
ihc
webster
et
al
probabl
true
common
antigen
demonstr
anim
sampl
autolysi
common
problem
diagnost
patholog
studi
address
effect
autolysi
ihc
shown
antigen
still
detect
despit
decomposit
howev
caution
interpret
autolyz
materi
necessari
due
loss
detect
antigen
maleszewski
et
al
necrot
tissu
tend
produc
background
normal
tissu
howev
ihc
necrot
tissu
provid
valuabl
inform
tissu
avail
particularli
cytokeratin
decalcifi
cation
formalinfi
xed
tissu
gener
reduc
immunoreact
antigen
particularli
use
weak
acid
loss
reactiv
appar
use
strong
acid
decalcifi
cation
affect
antigen
process
sampl
diagnost
ihc
routin
histopatholog
antigen
success
detect
formalinfi
xed
paraffi
nembed
ffpe
tissu
store
sever
decad
litlekalsoy
et
al
autolyz
sampl
biopsi
artifact
avoid
ihc
icc
sampl
mount
onto
silan
slide
polyllysineco
slide
charg
slide
allow
strong
bond
slide
tissu
section
pool
reagent
tissu
section
tissu
loss
occur
use
noncharg
slide
slide
without
special
coat
complet
deparaffi
nation
critic
achiev
optim
immunostain
deparaffi
nation
somewhat
cumbersom
commerci
product
perform
deparaffi
nation
antigen
retriev
simultan
although
result
may
complet
satisfactori
simpl
approach
deparaffi
nation
antigen
retriev
heat
recent
publish
boenisch
previous
mention
formalin
fi
xation
modifi
es
tertiari
structur
protein
often
render
antigen
undetect
specifi
c
antibodi
factor
bind
antibodi
antigen
conform
fi
may
modifi
ed
fi
xation
antigen
retriev
ar
intend
revers
chang
produc
fi
xation
addit
conform
chang
structur
protein
fi
xation
produc
major
chang
electrostat
charg
protein
antigen
critic
initi
attract
antigen
antibodi
therefor
recoveri
electrostat
charg
lost
formalin
fi
xation
propos
anoth
mechan
antigen
retriev
mani
protein
word
appear
one
mechan
may
involv
lack
recognit
antigen
antibodi
fi
xation
crosslink
fi
xativ
two
common
ar
procedur
includ
proteolyt
enzym
eg
pronas
trypsin
proteinas
k
immers
slide
buffer
high
temperatur
antibodi
may
react
differ
antigen
retriev
therefor
necessari
test
sever
method
optim
ihc
procedur
although
hier
procedur
appear
produc
optim
result
wide
varieti
antibodi
varieti
ar
method
avail
standard
ihc
method
among
laboratori
comparison
result
challeng
best
phosphatas
detect
method
block
procedur
use
enzym
mammalian
tissu
two
alkalin
phosphatas
isoenzym
nonintestin
form
easili
block
levamisol
intestin
isoform
unfortun
requir
acet
acid
block
chemic
damag
antigen
numer
tissu
endogen
avidinbiotin
activ
must
block
ad
biotinyl
reagent
avidinbiotin
detect
system
nonspecifi
c
bind
immunoglobulin
tissu
block
incub
tissu
section
bovin
serum
albumin
serum
speci
secondari
reagent
incub
primari
antibodi
commerci
avail
reagent
block
endogen
activ
nonspecifi
c
immunoglobulin
bind
immunohistochem
reaction
divid
immunolog
antigenantibodi
reaction
follow
demonstr
histochem
color
reaction
sensit
immunohistochem
reaction
mostli
result
detect
method
use
ramosvara
progress
regard
dramat
last
decad
two
main
enzym
use
ihc
peroxidas
alkalin
phosphatas
peroxidas
probabl
enzym
commonli
use
occas
particularli
heavili
pigment
sampl
sampl
rich
endogen
peroxidas
alkalin
phosphatas
excel
altern
current
ihc
method
divid
avidinbiotin
nonavidinbiotin
system
incub
primari
antibodi
secondari
antibodi
specifi
c
primari
antibodi
secondari
reagent
ad
avidinbiotin
system
secondari
reagent
biotinyl
avidinbiotin
method
tertiari
reagent
label
avidin
molecul
enzym
peroxidas
alkalin
phosphatas
need
common
nonavidinbiotin
method
base
polym
technolog
polym
contain
mani
molecul
secondari
antibodi
enzym
polym
method
usual
twostep
method
wherea
avidinbiotin
method
usual
threestep
method
polymerbas
method
fewer
step
endogen
avidinbiotin
background
problem
usual
sensit
beyond
scope
review
voss
et
al
detect
multipl
antigen
tissu
section
also
possibl
issu
keep
mind
doubl
multipl
immunostain
compat
ar
among
antigen
detect
type
primari
antibodi
polyclon
monoclon
cellular
local
antigen
color
chromogen
use
addit
substrat
enzym
use
plu
chromogen
produc
color
reaction
bind
antibodi
tissu
antigen
immunoperoxidas
method
common
chromogen
diaminobenzidin
dab
produc
brown
deposit
anoth
common
chromogen
aminoethylcarbazol
aec
alkalin
phosphatas
fast
blue
fast
red
common
chromogen
use
chromogen
need
coordin
counterstain
coverslip
method
like
ancillari
techniqu
ihc
need
standard
valid
optim
standard
new
antibodytest
process
serial
test
modifi
compon
procedur
eg
fi
xation
antigen
retriev
antibodi
dilut
detect
system
incub
time
etc
aim
produc
consist
highqual
assay
reader
advis
standard
everi
antibodi
use
hisher
laboratori
despit
exist
publish
protocol
ensur
optim
result
standard
includ
adequ
tissu
fi
xation
tissu
fi
xed
neutral
buffer
formalin
minimum
hour
everi
new
antibodi
test
follow
standard
protocol
includ
three
pretreat
antigen
retriev
ar
proteolyt
enzym
eg
proteinas
k
hier
eg
citrat
buffer
ph
four
twofold
dilut
primari
antibodi
standard
protocol
total
slide
initi
process
antibodi
includ
neg
reagent
control
pretreat
posit
control
section
use
standard
later
diagnost
set
one
antigen
question
detect
differ
method
eg
viru
isol
cellular
locat
known
neg
control
section
contain
cell
known
independ
method
lack
antigen
question
also
includ
usual
tissu
block
use
posit
control
use
neg
control
incub
primari
antibodi
done
room
temperatur
durat
vari
minut
hour
overnight
incub
usual
may
benefici
disrupt
autom
ihc
procedur
base
result
initi
procedur
optim
ar
method
dilut
primari
antibodi
select
slide
best
signal
specifi
c
stain
tonois
background
stain
ratio
stain
nonspecifi
c
suboptim
ar
method
dilut
test
keep
mind
antibodi
rais
human
antigen
may
reactiv
anim
tissu
standard
tissu
sampl
process
way
diagnost
sampl
eventu
test
test
valid
ihc
follow
standard
howev
time
consum
expens
seldom
done
veterinari
medicin
valid
test
examin
technic
aspect
effect
prolong
fi
xation
focus
abil
antibodi
use
marker
specifi
c
cell
tumor
infecti
agent
antibodi
use
tumor
marker
need
test
tumor
may
diffi
cult
distinguish
one
question
tumor
similar
phenotyp
eg
round
cell
tumor
routin
stain
tumor
present
locationorgan
valid
also
includ
evalu
stain
differ
among
differ
tumor
stain
differ
within
tumorsparticularli
differ
phenotyp
present
eg
spindl
epithelioid
melanoma
stain
differ
melana
differ
primari
metastat
tumor
valid
critic
given
rel
immunolog
promiscu
recognit
one
cell
type
tumor
antibodi
final
due
proven
variat
antibodi
reactiv
among
differ
speci
standard
valid
immunochem
procedur
must
done
speci
examin
immunocytochemistri
perform
type
cytolog
sampl
includ
cytospin
cell
smear
cell
block
liquidbas
monolay
prepar
fetsch
abati
cytospin
cell
smear
use
sampl
volum
small
advantag
cytospin
better
preserv
cytomorpholog
howev
icc
cytospin
cell
smear
liquidbas
monolay
prepar
thinprep
tend
produc
background
stain
barr
wu
cell
block
ffpe
thrombin
clot
method
choic
abund
cell
eg
effus
advantag
cell
block
similar
process
surgic
patholog
specimen
therefor
compar
result
possibl
prepar
multipl
section
block
eg
test
multipl
marker
eas
storag
cell
block
may
present
disadvantag
loss
cytomorpholog
loss
antigen
due
formaldehyd
fi
xation
brown
cell
block
prefer
nuclear
antigen
eg
pcna
wherea
airdri
cytospin
prefer
detect
surfac
antigen
eg
leukocyt
antigen
thinprep
less
suitabl
cell
block
detect
nuclear
antigen
gong
et
al
icc
may
perform
previous
stain
romanowski
papanicolau
slide
avail
specimen
produc
similar
result
unstain
slide
icc
stain
done
without
previou
destain
acid
alcohol
routin
stain
abendroth
dabb
barr
wu
miller
kubier
howev
technic
drawback
use
previous
stain
slide
loss
cell
slide
cell
disrupt
affect
mostli
icc
membran
cytoplasm
marker
signal
reduct
marker
eg
due
repeat
passag
sampl
grade
alcohol
case
slide
avail
area
contain
cell
larg
multipl
marker
test
simultan
altern
sampl
divid
follow
tissuetransf
techniqu
sherman
et
al
cytolog
slide
either
wetfi
xed
airdri
fi
xed
immedi
perform
icc
dabb
wetfi
xed
prepar
compar
airdri
sampl
signifi
cant
chang
term
cytolog
preserv
icc
stain
howev
airdri
prepar
may
lose
fewer
cell
wetfi
xed
sampl
airdri
prepar
store
week
immunostain
without
loss
antigen
fetsch
abati
sampl
put
plastic
microscop
slide
box
ziplock
plastic
bag
contain
desicc
sampl
equilibr
room
temperatur
bag
open
avoid
cell
ruptur
storag
sever
week
done
suthipintawong
et
al
one
main
problem
compar
qualiti
immunostain
cytolog
prepar
wide
rang
fi
xativ
fi
xation
protocol
use
differ
laboratori
issu
differ
diagnost
ihc
univers
fi
xativ
buffer
formaldehyd
use
instanc
give
gener
rule
laboratori
standard
valid
protocol
obtain
consist
result
fixat
necessari
preserv
cell
integr
multistep
immunostain
procedur
fixat
perform
immedi
immunostain
theoret
type
fi
xativ
select
antibodybyantibodi
basi
gener
lymphoid
melanoma
marker
sampl
fi
xed
minut
room
temperatur
aceton
epitheli
marker
minut
room
temperatur
alcohol
ethanol
mixtur
methanol
ethanol
nuclear
antigen
buffer
formalin
minut
fetsch
abati
author
favor
formal
salin
univers
fi
xativ
suitabl
antigen
leong
et
al
protein
gross
cystic
diseas
fl
uid
hormon
receptor
well
demonstr
ethanolfi
xed
sampl
due
cytoplasm
antigen
leakag
dabb
immunocytochem
method
parallel
immunohistochemistri
sever
step
previou
incub
primari
antibodi
eg
endogen
peroxidas
block
nonspecifi
c
bind
block
avidinbiotin
block
antigen
retriev
primari
antibodi
incub
secondari
sometim
tertiari
reagent
necessari
demonstr
immun
reaction
peroxidas
block
necessari
use
immunoperoxidas
techniqu
usual
method
h
deioniz
water
peroxidas
block
step
omit
acetonefi
xed
specimen
antigen
retriev
necessari
numer
occas
unfortun
rule
determin
priori
whether
antigen
retriev
need
method
optim
approach
standard
icc
similar
ihc
comprehens
list
antibodi
use
icc
nation
cancer
institut
includ
antibodi
sourc
dilut
primari
antibodi
fi
xation
antigen
retriev
method
avail
fetsch
abati
immunohistochemistri
ancillari
method
therefor
need
interpret
conjunct
clinicopatholog
data
includ
cytolog
surgic
biopsi
fi
nding
avail
case
ihc
consid
standalon
techniqu
human
veterinari
patholog
specifi
c
knowledg
right
stain
pattern
given
marker
extrem
import
determin
whether
stain
signifi
cant
interpret
icc
challeng
ihc
diffi
culti
obtain
posit
neg
control
sampl
treat
similar
way
test
sampl
addit
diffi
culti
distinguish
normal
neoplast
cell
stress
upcom
section
immunohistochem
diagnosi
metastat
tumor
antibodi
truli
specifi
c
singl
cell
type
interpret
ihc
reaction
base
expect
antibodi
person
profi
le
see
infi
deliti
tumorspecifi
c
marker
eg
reactiv
tcell
bcell
marker
yaziji
barri
simultan
presenc
antigen
one
cellular
compart
possibl
neoplast
cell
usual
result
diffus
protein
due
cellular
damag
process
detect
antigen
unusu
locat
interpret
caution
indic
immunohistochem
report
gener
speak
antibodi
use
ihc
use
icc
addit
antibodi
nonreact
surgic
biopsi
specimen
suitabl
cytolog
prepar
interpret
immunohistochem
reaction
requir
defi
nition
posit
neg
stain
controversi
issu
guidelin
given
marker
expect
present
cell
tumor
eg
cytokeratin
carcinoma
wherea
detect
marker
eg
uroplakin
iii
transit
cell
carcinoma
small
group
cell
consid
posit
result
perhap
recommend
recent
human
patholog
goldstein
et
al
statement
ihc
report
indic
intens
stain
percentag
posit
tumor
cell
would
inform
mere
posit
neg
result
provid
recent
veterinari
studi
et
al
lack
express
particular
antigen
may
signifi
cant
presenc
prognost
eg
absenc
express
progesteron
receptor
link
poor
outcom
human
breast
cancer
lack
express
combin
express
cutan
larg
bcell
lymphoma
link
short
surviv
bardou
et
al
sundram
et
al
human
patholog
ihc
antibodi
classifi
ed
class
devic
fda
mean
antibodi
consid
special
stain
adjunct
convent
histopatholog
diagnost
examin
rhode
word
except
ihc
standalon
techniqu
result
must
interpret
pathologist
context
diseas
ihc
test
eg
assay
er
pr
consid
class
ii
devic
potenti
predict
prognost
valu
similarli
veterinari
medicin
immunohistochem
result
part
patholog
report
need
interpret
pathologist
ramosvara
et
al
although
ihc
larg
displac
electron
microscopi
ancillari
techniqu
choic
diagnost
patholog
limit
fisher
one
main
problem
lack
standard
qualiti
control
among
laboratori
particularli
regard
antigen
retriev
interlaboratori
lack
reproduc
signifi
cant
deal
prognost
marker
mengel
et
al
interpret
immunostain
also
subject
wide
rang
interobserv
interpret
degre
knowledg
ihc
antibodi
use
requir
interpret
result
correctli
constitut
posit
result
percentag
posit
cell
need
intens
reaction
still
controversi
critic
issu
therapeut
decis
oncolog
tumor
express
specifi
c
marker
beyond
gener
one
make
test
multipl
marker
expens
unreward
neoplast
cell
upand
downregul
gene
express
result
lack
express
expect
antigen
express
new
antigen
issu
perhap
seriou
veterinari
medicin
degre
sophist
use
ihc
techniqu
advanc
human
patholog
exacerb
interspeci
differ
antigen
express
detect
common
caus
lack
stain
test
control
sampl
improp
procedur
fi
xation
immunocytochem
procedur
includ
antigen
retriev
antibodi
concentr
improp
counterstain
dabb
systemat
approach
entir
ihc
procedur
necessari
determin
caus
stain
failur
context
weak
stain
appli
posit
tissu
control
test
sampl
result
much
buffer
left
rins
step
excess
antibodi
dilut
insuffi
cient
incub
time
improp
storag
reagent
includ
buffer
antibodi
substrat
fetsch
abati
weak
stain
affect
test
sampl
might
result
loss
epitop
tissu
overfi
xation
multipl
caus
background
stain
common
one
inadequ
block
serum
protein
block
usual
done
normal
serum
protein
brown
bovin
serum
albumin
use
extens
past
block
reagent
nonspecifi
c
reaction
howev
recent
evid
ad
albumin
antibodi
diluent
solut
increas
background
immunohistochem
reaction
mittelbronn
et
al
caus
falseposit
stain
necrot
tissu
crush
cell
improp
fi
xation
incomplet
block
endogen
peroxidas
endogen
biotin
high
concentr
primari
antibodi
dabb
sampl
thick
tend
trap
reagent
produc
background
stain
carcinoma
cell
fl
uid
often
express
vimentin
lose
immunoreact
cytokeratin
antigen
shed
effus
fl
uid
absorb
onto
surfac
cell
present
fl
uid
antigen
cytolog
sampl
factor
viiirag
immunoglobulin
tend
diffus
surround
tissu
contribut
incorrect
interpret
immunostain
barr
wu
avoid
overstain
due
concentr
primari
antibodi
retitr
primari
antibodi
cytolog
prepar
recommend
caus
background
stain
includ
elsewher
ramosvara
use
detect
kit
recogn
primari
antibodi
made
goat
extens
background
posit
neg
control
observ
use
tissu
section
relat
speci
rumin
due
presenc
endogen
immunoglobulin
recogn
secondari
antibodi
antigoat
igg
similar
problem
observ
rabbit
monoclon
antibodi
test
rabbit
tissu
mous
monoclon
antibodi
test
mous
tissu
special
detect
procedur
commerci
avail
avoid
background
stain
although
exampl
nonspecifi
c
background
stain
import
immunocytochemistri
distinguish
posit
stain
normal
reactiv
cell
neoplast
cell
distinct
challeng
number
reactiv
cell
higher
neoplast
cell
eg
tcellrich
bcell
lymphoma
type
control
describ
ihc
use
icc
tissu
reagent
control
ideal
control
tissu
sampl
contain
antigen
interest
fi
xed
process
ident
way
test
sampl
ideal
posit
control
demonstr
immunoreact
weak
place
strong
other
neg
reagent
control
also
necessari
antibodi
test
see
fig
neg
reagent
control
either
irrelev
antibodi
nonimmun
serum
speci
primari
antibodi
ideal
ig
isotyp
monoclon
antibodi
replac
primari
antibodi
fetsch
abati
slide
neg
reagent
control
process
ident
manner
slide
primari
antibodi
neg
control
slide
use
assess
nonspecifi
c
stain
result
specifi
c
antigenantibodi
bind
background
stain
one
slide
avail
may
use
divid
test
neg
reagent
control
circl
area
interest
diamond
wax
pen
use
cell
transfer
techniqu
alreadi
mention
delelli
hoda
instanc
slide
neg
one
marker
use
test
second
marker
goal
diagnost
ihc
maxim
sensit
without
compromis
specifi
citi
result
typic
approach
cover
main
tumor
type
antibodi
panel
includ
cytokeratin
carcinoma
vimentin
sarcoma
melanoma
peripher
nerv
sheath
tumor
leukocyt
neoplasm
achiev
maximum
sensit
use
redund
antibodi
given
antigen
recommend
word
use
sever
antibodi
label
cell
type
tabl
list
cell
marker
use
immunochem
diagnosi
tumor
emphasi
organ
system
human
patholog
follow
expand
panel
propos
pancytokeratin
carcinoma
lymphoma
melana
gp
melanoma
vimentin
collagen
iv
sarcoma
yaziji
barri
marker
avail
reactiv
anim
tissu
altern
need
found
clinicopatholog
data
examin
judici
use
antibodi
best
approach
reduc
cost
test
need
explain
unexpect
reaction
client
particular
tumor
group
identifi
ed
eg
sarcoma
specifi
c
marker
determin
type
tumor
use
approach
base
b
c
figur
ap
troubleshoot
immunohistochemistri
tissu
section
cut
sever
week
immunohistochem
test
show
stain
result
tissu
section
age
b
compar
tissu
section
cut
fresh
immunohistochemistri
perform
show
nuclear
stain
sever
cell
c
clean
heat
unit
shown
help
avoid
fl
uctuat
incub
temperatur
note
buildup
salt
deposit
use
steamer
algorithm
fig
show
basic
algorithm
character
tumor
frequent
found
domest
speci
algorithm
approach
borrow
human
experi
unfortun
mani
marker
current
use
human
patholog
reactiv
anim
tissu
reactiv
differ
word
deal
ihc
anim
speci
antibodi
creat
equal
problem
compound
extens
test
valid
antibodi
use
human
diagnost
ihc
almost
nonexist
veterinari
medicin
lack
predict
behavior
percentag
posit
case
tumor
particular
antibodi
one
diffi
cult
barrier
overcom
veterinari
diagnost
ihc
use
particular
marker
also
determin
avail
laboratori
mani
antibodi
diagnost
prognost
signific
human
patholog
await
valid
similar
tumor
anim
capurro
et
al
similar
algorithm
approach
use
immunocytochemistri
antibodi
person
profi
le
apf
new
concept
introduc
yaziji
barri
apf
defi
ned
locat
expect
signal
eg
cytokeratin
exclus
cytoplasm
protein
calretinin
cytoplasm
nuclear
cell
membran
laminin
collagen
iv
found
interstitium
antibodi
pattern
produc
homogen
signal
cytokeratin
fi
lament
signal
chromogranin
melana
granular
signal
antibodycharacterist
pattern
across
tissu
tumor
thyroid
transcript
stain
neoplast
cell
pulmonari
carcinoma
uroplakin
iii
stain
small
percentag
tumor
cell
knowledg
profi
le
facilit
accur
interpret
immunohistochem
result
keep
mind
apf
may
vari
among
anim
speci
number
antibodi
avail
diagnost
purpos
increas
exponenti
last
year
give
diagnostician
opportun
make
defi
nitiv
diagnosi
keep
mind
regardless
number
marker
use
character
particular
tumor
gold
standard
attempt
ihc
care
examin
hestain
slide
reduc
number
marker
need
arriv
defi
nitiv
diagnosi
even
uncommon
make
defi
nitiv
diagnosi
one
marker
express
lack
thereof
protein
tumor
cell
may
differ
normal
cell
counterpart
upregul
downregul
gene
express
protein
codifi
ed
gene
common
neoplast
cell
use
tumor
marker
panel
diagnosi
metastat
diseas
key
improv
chanc
arriv
defi
nitiv
diagnosi
consid
rel
low
cost
ihc
expens
treat
tumor
clinician
keen
get
defi
nitiv
section
lymphoid
tissu
pretreat
hydrogen
peroxid
remov
endogen
peroxidas
activ
red
blood
cell
asterisk
contain
abund
endogen
peroxidas
activ
b
nonspecifi
c
dab
precipit
mimic
true
stain
c
border
section
asterisk
less
stain
center
due
loss
evapor
reagent
prolong
incub
case
lymphoma
stain
four
slide
show
result
two
marker
melana
marker
two
tissu
section
two
slide
one
slide
incub
primari
antibodi
slide
label
mel
one
slide
primari
antibodi
replac
nonimmun
serum
immunoglobulin
slide
label
control
advis
add
known
posit
control
slide
contain
test
tissu
section
case
posit
control
brownstain
tissu
upper
half
slide
case
posit
neg
melana
test
tissu
lower
half
slide
answer
pathologist
treatment
tailor
specifi
c
tumor
like
improv
qualiti
life
anim
propos
seri
step
character
metastat
tumor
modifi
ed
dabb
includ
determin
cell
line
differenti
use
major
lineag
marker
determin
cytokeratin
type
carcinoma
possibl
coexpress
vimentin
determin
express
cellspecifi
c
product
cellspecifi
c
structur
transcript
factor
uniqu
specifi
c
cell
type
main
differ
algorithm
approach
metastat
neuroendocrin
carcinoma
neuroendocrin
marker
pulmonari
carcinoma
neural
neoplasia
neural
marker
histiocyt
sarcoma
cd
tumor
without
know
locat
primari
tumor
differenti
diagnosi
includ
tumor
type
tumor
marker
panel
therefor
includ
antibodi
marker
includ
keratin
well
lymphoid
melanoma
sarcoma
marker
chijiwa
et
al
et
al
basic
panel
marker
small
anim
pancytokeratin
clone
mnf
panleukocyt
marker
melana
melanocyt
differenti
vimentin
mesenchym
differenti
cytokeratin
compris
approxim
polypeptid
differ
molecular
weight
number
separ
charg
acid
type
basic
type
ii
keratin
cytokeratin
pair
togeth
acid
basic
type
lowmolecular
weight
keratin
eg
ck
present
epithelia
except
squamou
epithelium
wherea
highmolecular
weight
keratin
eg
ck
typic
present
squamou
epithelium
almost
mesothelioma
carcinoma
except
squamou
cell
carcinoma
ck
coordin
express
ck
ck
one
criterion
classifi
carcinoma
human
patholog
approach
proven
use
metastat
carcinoma
undetermin
origin
one
paper
publish
regard
domest
anim
examin
wide
rang
carcinoma
dog
cat
express
ck
ck
espinosa
de
lo
montero
et
al
result
ck
similar
human
major
differ
observ
ck
among
anim
speci
ck
use
marker
myoepitheli
differenti
glandular
tumor
well
squamou
epithelium
mesotheli
cell
although
cytokeratin
typic
marker
epitheli
differenti
detect
mesenchym
tumor
melanoma
leiomyosarcoma
gastrointestin
stromal
tumor
liposarcoma
meningioma
angiosarcoma
although
usual
cell
oppos
diffus
strong
stain
carcinoma
sarcomatoid
carcinoma
dabb
coexpress
intermedi
fi
lament
report
certain
human
fetal
adult
tissu
carcinoma
frequent
express
vimentin
particularli
endometri
carcinoma
renal
cell
carcinoma
salivari
gland
carcinoma
spindl
cell
carcinoma
thyroid
follicular
carcinoma
case
coexpress
ck
vimentin
observ
colorect
mammari
prostat
ovarian
carcinoma
group
marker
includ
protein
glycoprotein
produc
cell
type
exact
function
protein
unknown
within
gener
neuroendocrin
marker
synaptophysin
chromogranin
commonli
use
specifi
c
group
tumor
antibodi
marker
work
well
anim
speci
keep
mind
synaptophysin
addit
stain
major
pheochromocytoma
adren
gland
may
stain
signifi
cant
number
adren
cortic
tumor
well
neuron
specifi
c
enolas
nse
anoth
classic
gener
neuroendocrin
marker
unfortun
marker
less
specifi
c
name
claim
stain
nonendocrin
cell
type
make
use
diagnost
ihc
question
recent
use
neuroendocrin
marker
veterinari
patholog
protein
gene
product
pgp
ubiquitin
hydrolas
label
mani
neuroendocrin
cell
also
label
unrel
tumor
antibodi
peptid
hormon
eg
thyroglobulin
calcitonin
glucagon
insulin
usual
crossreact
among
differ
anim
speci
demonstr
specifi
c
endocrin
cell
type
everi
year
numer
scientifi
c
paper
report
character
novel
marker
antibodi
extrem
specifi
c
particular
human
cell
tumor
eventu
releg
use
combin
antibodi
part
tumor
panel
section
present
marker
use
character
specifi
c
anim
tumor
thyroid
transcript
nuclear
transcript
factor
frequent
express
thyroid
tumor
common
follicular
also
present
medullari
tumor
pulmonari
tumor
ramosvara
et
al
tumor
includ
mesothelioma
usual
neg
hep
par
hepatocyt
paraffi
n
consist
detect
hepa
tocyt
tumor
stain
biliari
epithelium
make
good
choic
distinguish
tumor
particularli
use
conjunct
ck
ramosvara
et
al
howev
intestin
probabl
pancreat
tumor
posit
ramosvara
miller
melana
one
best
specifi
c
sensit
marker
melanoma
dog
less
sensit
felin
melanoma
certainli
specifi
c
classic
marker
nse
note
mani
steroidproduc
tumor
adren
cortex
testi
ovari
show
strong
reactiv
melana
ramosvara
et
al
uroplakin
iii
major
compon
asymmetr
unit
transit
epithelium
express
canin
transit
cell
carcinoma
conjunct
ck
number
transit
cell
carcinoma
detect
approach
ramosvara
et
al
uroplakin
iii
detect
nonurotheli
normal
neoplast
tissu
dog
make
marker
except
rule
coexpress
marker
differ
cell
type
marker
wide
use
human
patholog
discrimin
mesothelioma
carcinoma
calretinin
howev
attempt
use
canin
mesothelioma
varieti
antibodi
unreward
report
calretinin
stain
equin
mesothelioma
stoica
et
al
differenti
diagnosi
mesothelioma
pulmonari
carcinoma
challeng
human
patholog
numer
antibodi
test
recent
studi
indic
combin
calretinin
posit
mesothelioma
neg
lung
carcinoma
cea
neg
mesothelioma
posit
pulmonari
carcinoma
antibodi
econom
way
distinguish
two
type
tumor
mimura
et
al
desmin
detect
reactiv
mesotheli
cell
mesothelioma
carcinoma
cytolog
prepar
afi
fy
et
al
previous
mention
specifi
c
sensit
marker
canin
pulmonari
thyroid
carcinoma
use
cea
anim
tumor
limit
awar
stain
mesothelioma
anim
speci
use
cytokeratin
vimentin
usual
coexpress
mesothelioma
probabl
best
approach
distinguish
mesothelioma
pulmonari
carcinoma
anim
geninet
et
al
morini
et
al
sato
et
al
vural
et
al
smooth
musclespecifi
c
protein
calponin
evalu
canin
mammari
tumor
espinosa
de
lo
montero
et
al
addit
webster
et
al
studi
express
embryon
transcript
factor
canin
neoplasm
ihc
oncolog
use
tool
determin
tumor
prognosi
diseas
outcom
topic
intens
investig
human
patholog
without
controversi
prognost
marker
current
investig
anim
tumor
briefl
discuss
prolifer
marker
telomeras
activ
kit
stem
cell
factor
immunophenotyp
chang
cancer
progress
group
includ
pcna
cyclin
gener
indic
proport
proliferatingcycl
cell
given
tumor
marker
correl
well
mitot
index
malign
tumor
gener
prolifer
cell
benign
tumor
except
lymphoma
mammari
tumor
melanocyt
tumor
mast
cell
tumor
probabl
tumor
domest
speci
marker
studi
extens
ishikawa
et
al
kiupel
et
al
madewel
sakai
et
al
mast
cell
tumor
good
correl
decreas
surviv
time
index
histochem
detect
nuclear
organ
region
agnor
determin
rate
cellular
prolifer
gener
time
decreas
diseasefre
interv
webster
et
al
differ
studi
scase
et
al
agnor
score
consid
use
prognost
marker
canin
mast
cell
tumor
score
use
divid
patnaik
grade
mast
cell
tumor
group
show
markedli
differ
actual
surviv
time
pcna
score
correl
differ
surviv
time
sever
type
tumor
roel
et
al
scase
et
al
webster
et
al
prognost
signi
fi
canc
detect
cyclin
anim
tumor
fulli
evalu
murakami
et
al
telomer
portion
repetit
dna
protect
chromosom
degrad
loss
essenti
gene
cadil
et
al
cell
divis
telomer
progress
shorten
somat
cell
cell
undergo
replic
senesc
apoptosi
telomeras
ribonucleoprotein
enzym
complex
synthes
telomer
dna
normal
cell
telomeras
detect
male
germ
cell
activ
lymphocyt
len
tissu
stem
cell
popul
somat
cell
human
cancer
telomeras
activ
detect
case
dog
tumor
examin
express
telomeras
activ
kow
et
al
telomeras
express
dog
signifi
cantli
associ
tumor
prolifer
label
index
andor
tumor
grade
long
et
al
immunohistochem
detect
telomeras
could
use
prognost
marker
tool
determin
therapeut
approach
cancer
argyl
nasir
kit
protein
tyrosin
kinas
receptor
product
ckit
protooncogen
express
numer
tissu
cell
includ
mast
cell
mast
cell
tumor
immunohistochem
stain
pattern
kit
canin
mast
cell
tumor
use
prognost
tool
kiupel
et
al
normal
mast
cell
kit
local
cell
membran
local
within
cytoplasm
mast
cell
tumor
link
increas
rate
local
recurr
decreas
surviv
rate
increas
tumor
grade
reguera
et
al
observ
human
cancer
loss
redistribut
epitheli
marker
gain
mesenchym
marker
emt
usual
associ
one
follow
tumor
featur
increas
tumor
cell
motil
invas
potenti
tumor
grade
tumor
stage
baumgart
et
al
common
protein
affect
emt
epitheli
marker
ecadherin
betacatenin
plakoglobin
mesenchym
marker
ncadherin
vimentin
although
like
occur
publish
evid
emt
prognost
signifi
canc
cancer
domest
anim
ultrastructur
examin
tissu
cell
one
common
ancillari
method
use
diagnost
cytolog
patholog
dardick
et
al
marker
immunohistochemistri
structur
secretori
protein
specifi
c
cell
tissu
marker
electron
microscopi
em
subcellular
structur
organel
matrix
constitu
electron
microscopi
contribut
great
measur
understand
structur
featur
normal
patholog
tissu
although
use
em
declin
last
decad
partial
replac
techniqu
eg
immunohistochemistri
em
still
valuabl
tool
reach
defi
nitiv
diagnosi
diffi
cult
case
particularli
peripher
nerv
sheath
tumor
synovi
sarcoma
pleomorph
sarcoma
mesothelioma
dardick
herrera
mackay
em
ihc
use
complementari
fashion
base
type
diagnost
problem
fisher
ancillari
techniqu
em
rais
level
confi
denc
diagnos
base
light
microscopi
three
main
type
ancillari
techniqu
current
use
veterinari
patholog
em
ihc
pcr
em
matur
techniqu
mean
gone
usual
stage
develop
evalu
stabil
oppos
two
techniqu
still
develop
evalu
stage
say
goe
embrac
new
techniqu
worthi
keep
proven
old
one
method
examin
fi
ne
detail
tissu
cell
organel
inclus
pigment
extracellular
matrix
wealth
inform
ultrastructur
patholog
literatur
last
year
although
optim
formalinfi
xed
even
paraffi
nembed
tissu
use
identifi
infecti
agent
previous
report
therefor
without
specifi
c
antibodi
genet
probe
mani
microorgan
resist
autolysi
eukaryot
cell
therefor
warrant
ultrastructur
examin
suboptim
preserv
tissu
fig
tumor
reliabl
method
diagnosi
fig
certain
lesion
eg
glomerular
diseas
em
still
gold
standard
method
fig
immunolog
assay
perform
em
sampl
em
complement
immunohistochemistri
cellular
structur
nearli
ident
among
anim
speci
ultrastructur
level
ihc
contrast
unusu
unabl
demonstr
particular
antigen
new
speci
due
lack
interspeci
crossreact
sampl
prepar
rather
tediou
optim
prepar
achiev
special
fi
xation
patholog
chang
sometim
diffi
cult
distinguish
autolysi
process
artifact
sampl
may
repres
due
small
sampl
size
import
limit
factor
heterogen
lesion
pitfal
includ
presenc
necrot
normal
stromal
tissu
overal
expens
immunohistochemistri
requir
expens
equip
highli
skill
technician
examin
sampl
tediou
pathologist
extens
experi
interest
ultrastructur
patholog
endang
speci
principl
transmiss
electron
microscop
oper
similar
light
microscopei
lens
use
magnifi
imag
main
differ
use
produc
imag
type
radiat
em
electron
mean
focu
em
electromagnet
lens
resolv
power
electron
microscop
around
nm
less
much
higher
obtain
photon
microscop
nm
fl
uoresc
microscop
nm
process
sampl
em
basic
similar
light
microscopi
paraffi
nembed
sampl
reagent
use
differ
speed
fi
xation
critic
em
avoid
chang
due
autolysi
previous
mention
fi
xativ
choic
light
microscopi
formaldehyd
routin
electron
microscopi
glutaraldehyd
gold
standard
secondari
fi
xation
osmium
tetroxid
two
fi
xativ
complementari
glutaraldehyd
stabil
protein
osmium
tetroxid
stabil
lipid
glutaraldehyd
slower
diffus
rate
formaldehyd
small
sampl
around
mm
requir
optim
fi
xation
formaldehyd
optim
fi
xativ
diagnost
patholog
commonli
use
primari
fi
xativ
em
particularli
ultrastructur
studi
consid
initi
diagnost
workup
due
impur
commerci
avail
formaldehyd
solut
eg
formic
acid
methanol
ultrastructur
preserv
compromis
tissu
fi
xed
paraformaldehyd
aldehyd
formaldehyd
produc
amen
immunoelectron
microscopi
fi
xed
glutaraldehyd
fix
sampl
dehydr
embed
liquid
resin
polymer
produc
hard
block
cut
use
special
glass
diamond
knive
ultramicrotom
epoxi
resin
standard
embed
materi
special
procedur
eg
immunoelectron
microscopi
acryl
resin
lowicryl
lr
white
resin
prefer
bancroft
gambl
cell
suspens
fi
neneedl
aspir
cytolog
sampl
sampl
preembed
protein
medium
eg
agar
bovin
serum
albumin
semithin
section
fi
rst
cut
local
appropri
portion
sampl
section
approxim
thick
nm
silver
strawcolor
ultrathin
section
routin
section
usual
stain
uranyl
acet
lead
citrat
osmium
fi
xativ
also
stain
membran
lipid
vacuol
ffpe
tissu
use
sampl
avail
keep
mind
degre
preserv
organel
membran
ffpe
sampl
may
sever
compromis
b
toxoplasma
bradyzoit
conoid
arrow
micronem
mi
rhoptri
r
surround
cyst
wall
arrowhead
c
lung
pig
numer
pneumocysti
carinii
trophozoit
alveolar
surfac
note
type
one
type
pneumocyt
red
blood
cell
r
neutrophil
n
lymphocyt
l
three
trophozoit
one
cyst
c
form
note
cyst
thick
cell
wall
arrow
rudimentari
cytoplasm
asterisk
four
intracyst
bodi
sampl
select
interpret
electron
micrograph
heavili
bias
clinic
histori
light
microscopi
fi
nding
examin
ffpe
tissu
light
microscop
differenti
diagnos
made
addit
ancillari
techniqu
eg
em
ihc
request
character
lesion
examin
lesion
light
microscopi
pathologist
determin
featur
seek
ultrastructur
level
ultrastructur
examin
good
observ
may
fi
nd
addit
unexpect
featur
prompt
reconsider
origin
diagnosi
formalin
fi
xation
delay
fi
xation
probabl
creat
artifact
may
render
sampl
unsuit
thorough
ultrastructur
evalu
still
adequ
detect
specifi
c
featur
eg
viral
particl
parasit
inclus
crystal
buffer
formaldehyd
approxim
ph
reduc
loss
cellular
compon
tissu
shrinkag
sequenti
orderli
approach
ultrastructur
studi
tumor
involv
topograph
cellular
relationship
extern
lamina
cell
contour
intercellular
junction
cytoplasm
granul
cytoplasm
fi
lament
cytoplasm
vacuol
vesicl
type
distribut
organel
nuclear
nucleolar
morpholog
stroma
case
confl
ict
interpret
light
microscopi
electron
microscopi
reevalu
fi
nding
mandatori
rule
discrep
still
persist
light
microscopi
fi
nding
prevail
due
far
greater
amount
tissu
examin
howev
current
special
patholog
make
use
multipl
ancillari
techniqu
em
ihc
pcr
common
diffi
cult
case
care
evalu
result
need
made
establish
fi
nal
diagnosi
malign
determin
ultrastructur
ground
establish
malign
phenotyp
realm
light
microscopi
tumor
biolog
behavior
support
specifi
c
case
immunohistochem
molecular
test
tabl
intend
give
reader
gener
approach
ultrastructur
character
common
tumor
excel
atlas
ultrastructur
patholog
dickersin
dvorak
monahanearley
erlandson
eyden
ghadial
v
b
membran
glomerulonephr
cat
reveal
irregular
thicken
basement
membran
asterisk
glomerulu
basement
membran
multipl
immunecomplex
electrondens
deposit
long
arrow
note
fuse
foot
process
podocyt
arrowhead
lumen
capillari
vessel
l
surround
fenestr
line
short
arrow
also
shown
red
blood
cell
r
urinari
space
u
c
membran
glomerulonephr
dog
demonstr
irregular
thicken
basement
membran
contain
multipl
immunecomplex
electrondens
deposit
long
arrow
subepitheli
locat
short
arrow
note
microvilli
arrowhead
surfac
podocyt
p
canin
glomerulocyst
kidney
diseas
pariet
epithelium
e
hypertroph
distort
contain
abund
mildli
electrondens
materi
asterisk
associ
bowman
capsul
c
expand
extracellular
matrix
surround
urinari
space
u
term
special
stain
group
histochem
stain
use
histopatholog
arbitrarili
separ
standard
hematoxylineosin
special
stain
still
import
techniqu
character
numer
lesion
tissu
advent
immunohistochemistri
molecular
techniqu
special
stain
main
tool
character
lesion
beyond
major
laboratori
capabl
special
stain
equip
avail
routin
histopatholog
easi
usual
quick
produc
standard
reproduc
protocol
current
numer
special
stain
purchas
kit
use
automat
stainer
extens
valid
numer
variat
origin
protocol
produc
improv
qualiti
fairli
inexpens
detect
substanc
commerci
antibodi
detect
ihc
stain
somewhat
unpredict
due
natur
histochem
reaction
larg
chemic
group
rather
small
number
amino
acid
encompass
epitop
antigen
immunohistochemistri
short
sequenc
nucleic
acid
molecular
techniqu
detect
word
less
specifi
c
ihc
molecular
techniqu
numer
factor
contribut
dyetissu
affi
niti
includ
solventsolv
interact
eg
hydrophob
bond
enzym
substrat
stainstain
interact
eg
metachromat
stain
basic
dye
silver
impregn
reagenttissu
interact
coulomb
attract
eg
acid
basic
dye
van
der
waal
forc
eg
detect
larg
molecul
elast
fi
ber
hydrogen
bond
eg
stain
polysaccharid
carmin
acid
nonaqu
solut
coval
bond
eg
nuclear
detect
feulgen
reaction
pa
stain
bancroft
gambl
special
stain
use
mainli
demonstr
specifi
c
chemic
group
characterist
substanc
eg
glycogen
myelin
tabl
demonstr
gener
morpholog
microorgan
eg
fungi
bacteria
fig
tabl
excel
book
regard
special
stain
aspect
histotechnolog
bancroft
gambl
carson
prophet
cytomorpholog
alon
often
suffi
cient
cell
identifi
cation
mani
instanc
object
detail
identifi
cation
need
provid
diagnost
prognost
inform
flow
cytometri
valuabl
readili
avail
tool
allow
analysi
individu
cell
pass
front
laser
singl
cell
suspens
light
absorb
scatter
properti
cell
provid
inform
cell
size
intern
complexitygranular
respect
use
specifi
c
antibodi
allow
quantifi
cation
intracellular
surfaceexpress
compon
nucleu
nuclear
irregular
common
neoplast
cell
artifact
section
contain
portion
cytoplasm
pseudoinclus
nuclear
pocket
multipl
tumor
type
nonspecifi
c
featur
osteoclastlik
giant
cell
tumor
multilob
multipl
nuclear
profi
le
connect
thin
bridg
multinuclear
nuclear
profi
le
join
hydroxyapatit
deposit
collagen
fi
ber
osteoid
wide
use
clinic
applic
involv
incub
cell
fl
uoresc
label
antibodi
direct
surfac
antigen
allow
determin
frequenc
cell
express
given
molecul
well
rel
express
level
individu
cell
antibodi
label
varieti
fl
uorochrom
differ
excit
emiss
wavelength
express
sever
surfac
molecul
detect
simultan
major
advantag
fl
ow
cytometri
allow
rapid
object
identifi
cation
larg
number
cell
clinic
fl
ow
cytometri
gener
use
analysi
hematopoiet
cell
order
character
lymphoma
leukemia
quantifi
cell
case
suspect
immunolog
disord
analyz
sampl
fl
ow
cytometri
cell
must
suspens
free
clump
debri
anticoagul
whole
blood
caviti
effus
gener
submit
directli
fl
ow
cytometri
facil
analysi
aspir
solid
tissu
resuspend
media
serum
univers
laboratori
set
tissu
cultur
media
rpmi
dmem
buffer
hepe
supplement
fetal
bovin
serum
ideal
howev
clinic
set
salin
use
serum
patient
ad
serum
anoth
patient
speci
may
also
use
minimum
cell
need
antibodi
combin
sever
tissu
aspir
need
complet
analysi
sampl
ship
must
ship
overnight
cold
pack
prepar
cell
fl
ow
cytometri
vari
wide
laboratori
lana
et
al
rusland
et
al
vernau
moor
villier
et
al
wilkerson
et
al
present
consensu
best
method
commonli
fi
rst
step
cell
prepar
remov
red
blood
cell
lysi
hypoton
solut
altern
method
prepar
cell
differenti
densiti
centrifug
solut
histopaqu
neutrophil
red
blood
cell
platelet
pass
solut
wherea
mononuclear
cell
remain
top
histopaqu
layer
techniqu
concentr
mononuclear
cell
consider
possibl
cell
interest
may
pass
densiti
gradient
lost
analysi
analysi
antigen
express
cell
surfac
cell
incub
antibodi
cell
surfac
marker
primari
antibodi
either
unlabel
directli
conjug
fl
uoresc
molecul
call
fl
uorochrom
directli
conjug
antibodi
visual
immedi
stain
greatli
facilit
use
multipl
marker
simultan
cell
stain
unlabel
antibodi
must
subject
second
stain
reaction
use
label
antibodi
recogn
immunoglobulin
portion
primari
antibodi
gener
singl
unconjug
antibodi
use
stain
reaction
prevent
simultan
quantifi
cation
multipl
marker
individu
cell
import
includ
control
reaction
sampl
control
consist
cell
left
unstain
cell
stain
antibodi
isotyp
specif
bind
antigen
cell
interest
unstain
cell
allow
oper
correct
autofl
uoresc
fl
uoresc
intens
irrelev
antibodi
reaction
use
determin
level
background
stain
laboratori
use
varieti
differ
antibodi
differ
combin
immunophenotyp
tabl
list
suggest
panel
dog
cat
although
laboratori
includ
use
extens
array
antibodi
largest
supplier
directli
conjug
antibodi
use
routin
veterinari
fl
ow
cytometri
abd
serotec
wwwabdirectcom
clone
list
tabl
avail
compani
supplier
r
system
www
rndsystemscom
bd
bioscienc
wwwbdbioscienc
com
southern
biotech
wwwsouthernbiotechcom
cat
fewer
antibodi
cell
wash
fi
nal
stain
reaction
either
fi
xed
paraformaldehyd
later
analysi
analyz
immedi
without
fi
xation
cell
analyz
immedi
addit
stain
propidium
iodid
label
cell
disrupt
cell
membran
therefor
use
exclud
dead
cell
analysi
techniqu
extrem
use
dead
cell
tend
nonspecifi
calli
bind
antibodi
addit
surfac
molecul
sever
use
antigen
locat
within
cell
cytoplasm
exampl
human
tcell
acut
lymphoblast
leukemia
lack
surfac
express
cytoplasm
express
szczepanski
et
al
reagent
commonli
use
ihc
dog
also
use
fl
ow
cytometri
wilkerson
et
al
could
includ
panel
use
phenotyp
acut
leukemia
monocytegranulocyt
lineag
marker
myeloperoxidas
mpo
also
cytoplasm
use
analyz
acut
myeloid
origin
leukemia
villier
et
al
order
expos
cytoplasm
molecul
cell
membran
must
permeabil
use
commerci
avail
permeabil
reagent
stain
import
aspect
fl
ow
cytometri
data
analysi
begin
examin
light
scatter
properti
cell
cell
pass
front
laser
scatter
light
detector
record
amount
forwardscatt
sidescatt
light
total
amount
forwardscatt
light
detect
depend
cell
surfac
area
size
wherea
amount
sidescatt
light
indic
cellular
complex
granular
figur
demonstr
typic
scatter
plot
canin
peripher
blood
dot
repres
individu
cell
place
rel
amount
forward
side
scatter
record
pass
front
laser
typic
scatter
properti
allow
identifi
cation
lymphocyt
monocyt
neutrophil
popul
although
consensu
analysi
method
veterinari
medicin
gener
fi
rst
step
analysi
gate
differ
popul
cell
base
scatter
properti
shown
figur
lymphocyt
lower
forward
side
scatter
wherea
neutrophil
higher
forward
side
scatter
monocyt
fall
next
step
determin
percentag
cell
within
popul
express
marker
interest
look
fl
uoresc
profi
le
popul
fl
uorochrom
use
label
antibodi
excit
laser
emit
particular
peak
emiss
wavelength
detect
fl
ow
cytomet
differ
fl
uorochrom
distinct
peak
emiss
wavelength
antibodi
conjug
two
differ
fl
uorochrom
use
simultan
one
stain
reaction
amount
fl
uoresc
signal
detect
proport
number
fl
uorochrom
molecul
cell
data
display
singl
paramet
form
histogram
two
paramet
display
simultan
dot
plot
fig
twoparamet
dot
plot
allow
individu
eventscel
display
rel
fl
uoresc
two
individu
marker
display
electron
gate
differ
popul
allow
user
determin
percentag
cell
popul
posit
given
molecul
see
fig
percentag
posit
cell
usual
determin
fi
rst
analyz
isotyp
control
set
gate
base
control
percentag
posit
cell
determin
number
cell
fall
gate
set
neg
control
see
fig
isotyp
control
use
guidelin
gener
accept
fl
exibl
placement
gate
includ
logic
popul
cell
laboratori
report
fl
ow
cytometri
data
differ
peripher
blood
analysi
use
inform
absolut
number
lymphocyt
subset
peripher
blood
per
microlit
percentag
report
may
diffi
cult
distinguish
loss
one
popul
expans
anoth
popul
although
normal
valu
publish
byrn
et
al
prepar
method
differ
wide
laboratori
lab
gener
normal
valu
sampl
percentag
lymphocyt
subset
report
usual
gate
relev
popul
size
exampl
lymph
node
aspir
dog
lymphoma
neoplast
lymphocyt
usual
larg
therefor
percentag
lymphocyt
subset
determin
gate
larg
cell
addit
percentag
cell
express
differ
marker
cell
abnorm
phenotyp
loss
antigen
aberr
express
antigen
also
describ
quantifi
ed
routin
immunophenotyp
circul
lymphocyt
becom
preval
veterinari
medicin
crossreact
speciesspecifi
c
antibodi
becom
avail
number
studi
describ
immunophenotyp
marker
canin
lymphoma
leukemia
appelbaum
et
al
day
caniatti
et
al
rusland
et
al
grindem
et
al
mcdonough
moor
modiano
et
al
ponc
et
al
distinguish
reactiv
neoplast
process
often
fi
rst
task
face
clinician
find
phenotyp
homogen
popul
lymphocyt
suggest
neoplast
rather
reactiv
process
exampl
canin
chronic
lymphocyt
leukemia
cll
commonli
involv
expans
cell
less
frequent
b
cell
vernau
moor
workman
vernau
cell
usual
compris
canin
peripher
blood
b
cell
usual
compris
byrn
et
al
greeley
et
al
leukemia
would
primari
differenti
diagnosi
dog
persist
lymphocytosi
major
peripher
blood
lymphocyt
b
cell
although
criteria
establish
veterinari
medicin
make
distinct
rare
except
interpret
dog
would
lymphocytosi
ehrlichia
cani
infect
associ
select
expans
cell
heeb
et
al
mcdonough
moor
weiser
et
al
knowledg
exampl
cat
studi
predict
valu
expand
lymphocyt
popul
absolut
lymphocyt
count
use
defi
ne
leukemia
would
import
clinic
use
present
report
avail
veterinari
literatur
aberr
express
surfac
molecul
provid
defi
nitiv
diagnosi
leukemia
lymphoma
rezuk
et
al
reactiv
lymphocyt
gener
retain
express
normal
constel
antigen
human
tcell
leukemia
character
tendenc
lose
express
normal
tcell
antigen
express
aberr
combin
antigen
jen
foon
exampl
one
studi
human
malign
tcell
disord
complet
loss
tcell
antigen
panleukocyt
antigen
diagnost
malign
gorczyca
et
al
order
detect
aberr
antigen
express
use
examin
larg
panel
antigen
use
multicolor
fl
uoresc
protocol
experi
loss
panleukocyt
marker
common
form
aberr
antigen
express
tcell
leukemia
smaller
number
case
document
lost
express
vernau
moor
despit
util
help
diagnos
tcell
leukemia
decreas
express
appear
associ
prognosi
william
et
al
studi
canin
multicentr
lymphoma
consist
demonstr
immunophenotyp
b
versu
provid
prognost
use
inform
conjunct
clinic
stage
rusland
et
al
tesk
et
al
tcell
lymphoma
typic
wors
prognosi
bcell
lymphoma
import
note
howev
histolog
subtyp
cell
lymphoma
ponc
et
al
good
prognosi
histolog
subtyp
bcell
lymphoma
poor
prognosi
raskin
fox
human
medicin
surfac
marker
identifi
ed
help
distinguish
histolog
subtyp
lymphoma
via
fl
ow
cytometri
yet
reach
point
veterinari
medicin
immunophenotyp
ideal
combin
histolog
subtyp
peripher
lymphocytosi
willliam
et
al
examin
immunophenotyp
canin
lymphoprolif
disord
involv
peripher
lymphocytosi
without
distinguish
lymphoma
leukemia
prognost
signifi
canc
analyz
peripher
blood
sampl
immunophenotyp
plu
one
addit
clinic
cellular
featur
allow
dog
circul
neoplast
lymphocyt
place
good
poor
prognost
categori
bcell
disord
size
circul
lymphocyt
prognost
larger
b
cell
associ
shorter
surviv
tcell
disord
lymphocyt
count
prognost
case
lymphocytesl
shorter
surviv
time
william
et
al
acut
leukemia
diagnos
cellular
morpholog
long
known
poor
prognosi
use
anticanin
marker
gener
found
precursor
lymphocyt
use
object
identi
fy
case
acut
leukemia
like
express
aml
villier
et
al
workman
vernau
present
publish
studi
examin
distribut
differ
leukem
subtyp
addit
tradit
classifi
cation
scheme
acut
leukemia
reli
cellular
morpholog
alon
correl
blast
morpholog
express
establish
despit
fact
recent
work
document
signifi
cantli
shorten
surviv
time
dog
increas
number
circul
cell
william
et
al
often
blast
identifi
ed
peripher
blood
bone
marrow
diffi
cult
assign
cell
lineag
fl
ow
cytometri
extrem
use
case
although
report
publish
correl
morpholog
characterist
immunophenotyp
cytoplasm
stain
acut
leukemia
may
use
surfac
stain
human
tcell
express
cytoplasm
szczepanski
et
al
b
cell
marker
locat
cytoplasm
leukemia
stain
either
marker
gener
classifi
ed
lymphoid
cell
stain
surfac
marker
classifi
ed
myeloid
intracellular
stain
antibodi
myeloperoxidas
use
antibodi
may
provid
confi
rmation
myeloid
origin
cell
excel
studi
correl
aml
subclassifi
cation
immunophenotyp
use
varieti
marker
villier
et
al
similar
studi
avail
particularli
use
applic
fl
ow
cytometri
involv
distinguish
lymphoma
thymoma
case
lymphocyterich
mediastin
mass
lana
et
al
thymic
lymphocyt
coexpress
marker
wherea
cell
express
either
proport
lymphocyt
associ
neoplast
epitheli
tissu
thymoma
coexpress
phenotyp
togeth
small
size
cell
diagnost
thymoma
fig
lymphoma
involv
mediastinum
gener
cell
express
one
neither
subset
marker
sinc
make
distinct
lymphoma
thymoma
determin
whether
patient
chemotherapi
surgeri
particularli
import
use
assay
complementari
fl
ow
cytometri
imag
analysi
imag
analysi
measur
count
microscop
imag
order
obtain
inform
diagnost
import
although
imag
analysi
exist
time
advent
computerassist
analysi
led
rapid
sensit
quantit
method
evalu
meijer
et
al
typic
televis
camera
receiv
imag
light
microscop
signal
convert
digit
interfac
comput
creat
digit
cell
imag
display
monitor
imag
analysi
divid
three
differ
area
exampl
cellular
morphometri
count
cellular
compon
cytometri
morphometri
quantit
descript
geometr
featur
cellular
structur
dimens
count
cellular
compon
object
count
usual
appli
assess
cell
kinet
evalu
prolif
marker
tumor
allow
quantit
prolif
fraction
number
mitos
cell
popul
shown
use
evalu
biolog
behavior
tumor
prolifer
marker
includ
bromodeoxyuridin
brdu
prolifer
cell
nuclear
antigen
pcna
agnor
method
dna
cytometri
measur
dna
content
tumor
cell
use
marker
malign
oncolog
imag
cytometri
use
measur
amount
icc
ihc
stain
protein
cell
laser
scan
cytometri
newer
technolog
scan
cell
slide
evalu
fl
ow
cytometri
type
analysi
darzynkiewicz
et
al
laser
cytometri
permit
observ
view
cell
correl
fl
ow
cytometri
data
directli
cell
measur
classifi
cell
standard
morpholog
criteria
human
medicin
determin
clonal
detect
clonal
rearrang
antigen
receptor
gene
often
test
choic
routin
cytolog
histolog
immunophenotyp
abl
provid
defi
nitiv
diagnosi
lymphoid
malign
swerdlow
clonal
test
base
observ
lymphocyt
mount
divers
respons
antigen
whether
deriv
environ
allergen
pathogen
self
autoantigen
contrast
malign
lymphocyt
homogen
aris
singl
transform
cell
normal
lymphocyt
differenti
depend
process
antigen
receptor
rearrang
therefor
matur
lymphocyt
antigen
receptor
gene
undergon
vj
vdj
rearrang
immunoglobulin
gene
rearrang
b
lymphocyt
tcell
receptor
gene
andor
lymphocyt
jung
alt
process
fig
nucleotid
trim
ad
gene
recombin
result
signifi
cant
length
sequenc
heterogen
particularli
within
complementar
determin
region
divers
within
bcell
immunoglobulin
gene
creat
somat
hypermut
antigendriven
b
cell
activ
end
result
differenti
divers
popul
lymphocyt
virtual
limitless
antigen
specifi
citi
larg
varieti
sequenc
length
lymphocyt
deriv
clone
region
length
sequenc
term
parr
use
distinguish
type
pcr
assay
method
determin
clonal
addit
mean
determin
clonal
human
medicin
would
includ
amplifi
cation
gene
chromosom
transloc
bring
bcl
igh
loci
togeth
rel
common
human
b
cell
lymphoma
van
dongen
et
al
principl
behind
assay
describ
detail
workman
vernau
step
carri
clonal
assay
begin
dna
extract
tissu
virtual
type
tissu
use
sourc
dna
includ
blood
caviti
fl
uid
aspir
csf
stain
unstain
cytolog
prep
tissu
paraffi
n
block
latter
least
desir
formalin
fi
xation
degrad
dna
result
fals
neg
fals
posit
primer
hybrid
conserv
portion
v
j
region
gene
immunoglobulin
tcell
receptor
gene
use
amplifi
dna
pcr
reaction
although
tcell
receptor
either
primer
recogn
use
sinc
fewer
gene
fewer
primer
need
detect
major
malign
rearrang
clonal
even
malign
ultim
express
human
medicin
primer
recogn
well
vj
dj
bcligh
rearrang
use
detect
clonal
van
dongen
et
al
analysi
pcr
product
carri
use
varieti
method
design
evalu
size
product
case
sequenc
heterogen
polyacrylamid
gel
electrophoresi
separ
pcr
product
size
presenc
domin
singles
product
indic
presenc
group
lymphocyt
share
ident
size
region
eg
clonal
expand
presenc
variabl
size
product
suggest
polyclon
popul
lymphocyt
gel
electrophoresi
use
gel
must
abil
resolv
product
three
base
pair
differ
size
thu
agaros
gel
use
altern
method
includ
heteroduplex
analysi
resolv
product
size
sequenc
heterogen
thu
may
provid
resolv
power
capillari
gel
electrophoresi
separ
product
size
less
time
consum
melt
curv
analysi
xu
et
al
use
syber
green
technolog
also
reli
size
sequenc
heterogen
figur
show
pcr
product
separ
size
use
polyacrylamid
gel
electrophoresi
burnett
et
al
case
posit
control
lane
confi
rm
presenc
dna
posit
control
dna
amplifi
ed
primer
give
singl
product
therebi
confi
rming
rel
quantiti
qualiti
extract
dna
two
set
primer
use
amplifi
immunoglobulin
gene
separ
reaction
lane
two
set
primer
use
one
v
region
gene
human
genom
recombin
randomli
select
region
gene
j
region
gene
loop
interven
dna
b
process
nucleotid
ad
black
bar
gene
gener
length
sequenc
divers
complementar
determin
region
differenti
size
dna
separ
polyacrylamid
gel
appear
ladder
repres
differ
popul
b
cell
shown
left
c
primer
homolog
conserv
framework
region
v
j
region
arrow
amplifi
pcr
product
differ
size
dna
deriv
differ
lymphocyt
primer
locat
outsid
hypervari
amplifi
lane
reaction
technic
reason
arrang
amplifi
cation
result
product
exampl
lane
panel
smear
lane
panel
singles
pcr
product
lane
panel
multipl
discret
product
lane
panel
c
smear
product
interpret
neg
result
evid
clonal
one
promin
discret
product
consid
posit
result
indic
presenc
clonal
expand
popul
figur
dog
panel
clonal
b
cell
popul
dog
panel
b
c
clonal
cell
popul
common
posit
result
one
two
pcr
product
two
pcr
product
like
result
rearrang
chromosom
tumor
howev
unusu
see
multipl
rearrang
kisseberth
et
al
reason
two
discret
pcr
product
clear
may
also
possibl
deriv
origin
neoplast
clone
underw
addit
recombin
event
question
may
resolv
sequenc
individu
pcr
product
yet
done
import
laboratori
develop
assay
provid
sensit
specifi
citi
number
assaypublish
result
one
laboratori
translat
anoth
wide
variat
way
assay
carri
author
laboratori
sensit
assay
canin
case
histolog
cytolog
confi
rmed
lymphoma
leukemia
reason
fals
neg
result
may
possibl
gener
primer
detect
v
j
region
gene
malign
use
gene
pri
mer
hybrid
malign
lost
chromosom
carri
antigen
receptor
gene
somat
hypermut
case
bcell
lymphoma
leukemia
alter
sequenc
primer
hybrid
malign
nk
origin
therefor
contain
rearrang
antigen
receptor
gene
presenc
clonal
popul
specifi
c
malign
case
clonal
popul
b
cell
lymphoprolif
diseas
includ
singl
case
lyme
diseas
rocki
mountain
spot
fever
bartonella
infect
sever
case
ehrlichia
cani
infect
like
addit
reason
detect
clonal
lymphocyt
popul
nonneoplast
condit
need
determin
clonal
test
avail
dog
cat
routin
basi
fi
rst
largescal
studi
techniqu
report
burnett
et
al
follow
earlier
studi
demonstr
presenc
clonal
rearrang
tcell
receptor
gene
canin
malign
dreitz
et
al
fivenson
et
al
vernau
moor
common
applic
techniqu
case
cytolog
histolog
ambigu
assay
detect
neoplast
cell
within
popul
normal
cell
burnett
et
al
use
earli
case
lymphoma
leukemia
stain
unstain
cytolog
slide
cell
freshli
aspir
edta
tube
best
sampl
purpos
interpret
result
vari
depend
sensit
specifi
citi
assay
laboratori
offer
test
sinc
parr
assay
sensit
visual
examin
cell
detect
neoplast
cell
peripher
blood
detect
cytolog
keller
et
al
approxim
stage
iii
lymphoma
visual
detect
circul
neoplast
cell
result
peripher
blood
lana
et
al
presenc
cell
appear
correl
wors
outcom
howev
clinic
stage
remain
use
predictor
prognosi
may
possibl
use
parr
monitor
progress
diseas
follow
chemotherapi
predict
relaps
clinic
evid
applic
yet
explor
sequenc
region
amplifi
ed
pcr
process
uniqu
lymphocyt
clone
therefor
sequenc
use
establish
relationship
neoplast
cell
aris
differ
place
bodi
aris
differ
time
dramat
differ
morpholog
appear
exampl
relationship
helicobact
pylori
infect
human
gastric
lymphoma
establish
show
bcell
lymphoma
patient
histori
helicobact
infect
sequenc
clone
found
reactiv
gastriti
biopsi
specimen
obtain
sever
year
earlier
zucca
et
al
uniqu
sequenc
use
determin
two
tumor
morpholog
differ
phenotyp
relat
brauning
et
al
describ
two
human
patient
two
distinct
form
lymphoma
occur
simultan
patient
classic
hodgkin
lymphoma
one
also
follicular
lymphoma
cellrich
bcell
lymphoma
sequenc
immunoglobulin
gene
reedsternberg
cell
hodgkin
lymphoma
ident
sequenc
form
bcell
lymphoma
patient
fi
nding
indic
singl
clone
evolv
dramat
differ
morpholog
phenotyp
burnett
et
al
carri
similar
studi
dog
treat
classic
nonhodgkin
bcell
lymphoma
develop
multipl
myeloma
sequenc
region
tumor
shown
b
cell
lymphoma
plasma
cell
multipl
myeloma
clonal
origin
sequenc
immunoglobulin
gene
cat
publish
use
clonal
assay
case
viscer
bcell
lymphoma
intestin
tcell
lymphoma
werner
et
al
studi
use
primer
case
felin
intestin
lymphoma
sensit
cell
primer
sensit
b
cell
primer
laboratori
appli
form
felin
lymphoma
leukemia
primer
current
detect
approxim
confi
rmed
felin
lymphoma
leukemia
addit
primer
develop
attempt
increas
sensit
assay
particularli
use
distinguish
infl
ammatori
bowel
diseas
lymphoma
cat
distinct
often
diffi
cult
make
histolog
lymphoma
leukemia
frequent
associ
transloc
process
recombin
antigen
receptor
gene
leav
lymphocyt
suscept
mistak
recombin
transloc
found
human
leukemia
lymphoma
involv
immunoglobulin
heavi
chain
gene
locu
exampl
transloc
juxtapos
locu
encod
cyclin
chromosom
immunoglo
bulinenhanc
sequenc
chromosom
transloc
result
overexpress
cyclin
found
virtual
case
mantl
cell
lymphoma
campo
detect
translo
cation
pcr
overexpress
protein
immunohistochemistri
use
confi
rm
diagnosi
mantl
cell
lymphoma
histolog
ambigu
case
recent
consortium
european
research
found
combin
use
clonal
determi
nation
antigen
receptor
rearrang
togeth
detect
transloc
pcr
result
detect
clonal
popul
case
confi
rmed
lymphoid
malign
van
krieken
et
al
chromosom
aberr
detect
dog
convent
karyotyp
hahn
et
al
compar
genom
hybrid
thoma
et
al
aberr
includ
gain
loss
portion
chromosom
well
balanc
transloc
differ
chromosom
assay
use
detect
chromosom
chang
yet
amen
routin
diagnost
test
may
suffi
cientli
sensit
detect
earli
malign
small
number
malign
cell
within
popul
reactiv
cell
despit
fact
studi
sort
almost
certainli
lead
discoveri
target
pcr
immunohistochemistri
fl
ow
cytometrybas
assay
use
detect
malign
lymphocyt
ambigu
case
primari
util
parr
assay
help
establish
presenc
lymphoma
leukemia
case
routin
diagnost
test
ambigu
exampl
situat
parr
use
includ
lymph
node
aspir
lymphoma
suggest
conclud
eg
predomin
small
interm
diates
lymphocyt
mild
expans
intermediates
larg
lymphocyt
lymphocyterich
nonchyl
effus
increas
plasma
cell
number
marrow
flow
cytometri
fi
rst
test
choic
anim
peripher
lymphocytosi
case
cytolog
histolog
confi
rmed
lymphoma
fl
ow
cytometri
immunohistochemistri
immunocytochemistri
best
method
immunophenotyp
diagnost
dilemma
involv
lymphoprolif
disord
type
test
use
note
list
appli
dog
cat
fl
ow
cytometri
parr
less
reward
cat
fewer
antibodi
fl
ow
cytometri
speci
result
less
complet
character
lymphoprolif
diseas
parr
assay
current
less
sensit
cat
